OHRP Insider Trading Activity and SEC Form 4 Filings
OHRP insider trading summary
No open-market insider purchases or sales of Ohr Pharmaceutical Inc (OHRP) have been reported on SEC Form 4 in the past 12 months.
Latest OHRP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 10, 2017 | Orin Hirschman | Director | Buy | $100K (142,858 @ $0.70) |
| Apr 10, 2017 | Jason Scott Slakter | Chief Executive Officer | Buy | $100K (142,858 @ $0.70) |
| Apr 10, 2017 | Samuel Backenroth | Chief Financial Officer | Buy | $50K (71,429 @ $0.70) |
| Jun 20, 2016 | Jason Scott Slakter | Chief Executive Officer | Buy | $245 (85 @ $2.88) |
| Jun 20, 2016 | Samuel Backenroth | Chief Financial Officer | Buy | $23 (8 @ $2.88) |
| Jun 20, 2016 | Jason Scott Slakter | Chief Executive Officer | Buy | $3 (1 @ $2.83) |
| Jun 20, 2016 | Samuel Backenroth | Chief Financial Officer | Buy | $29 (10 @ $2.89) |
| Jun 20, 2016 | Jason Scott Slakter | Chief Executive Officer | Buy | $5K (1,700 @ $2.89) |
| Jun 20, 2016 | Samuel Backenroth | Chief Financial Officer | Buy | $1K (450 @ $2.87) |
| Jun 20, 2016 | Samuel Backenroth | Chief Financial Officer | Buy | $542 (200 @ $2.71) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.